Suppression of collagen-induced @entity625 using an angiogenesis inhibitor, @entity10822 , and a microtubule stabilizer, XXXX .

@entity625 @entity10822 @entity2295 @entity1311 @entity1753 @entity2070 @entity35 @entity309
@entity1753 ( @entity1753 ) is a T-cell-dependent @entity35 model of @entity309 ( @entity309 ) that is induced by injection of collagen type II in incomplete Freund's adjuvant. @entity2295 within the synovium is a prominent feature of @entity1753 and @entity309 . The novel angiogenesis inhibitor @entity10822 and the microtubule-stabilizing agent Taxol represent two new classes of agents with specific mechanisms of action. @entity10822 inhibits fibroblast growth factor-induced stimulation of endothelial cell migration, endothelial cell proliferation, and capillary tube formation, resulting in effective suppression of new blood vessel formation. By enhancing microtubule polymerization, Taxol interferes with normal microtubule function in cell mitosis, migration, chemotaxis, and intracellular transport. Using a suppression protocol in established @entity1753 , the effects of @entity10822 and Taxol as single agents and in combination were evaluated. Combination therapy significantly reduced clinical @entity625 compared to control @entity35 (P < 0.00001). The combination therapy group also experienced earlier and significantly greater reduction of clinical @entity625 compared to either single agent-treated groups (P < 0.05). Blinded radiographic scores at the end of the study demonstrated less soft tissue swelling and joint destruction using combination therapy than either single agent. This is the first use of @entity10822 and @entity1311 in combination therapy. Further study of agents with distinct mechanisms of action may lead to more effective treatment options in chronic @entity625 and to a better understanding of the pathophysiologic processes of @entity2070 formation.
